<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27405" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Secondary Polycythemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haider</surname>
            <given-names>Mobeen Z.</given-names>
          </name>
          <aff>King Edward Medical University, Lahore, Pakistan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anwer</surname>
            <given-names>Faiz</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mobeen Haider declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faiz Anwer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27405.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Secondary polycythemia is a rare disease that involves the overproduction of red blood cells. The overproduction of the red cells can be due to a number of reasons ranging from genetic abnormalities to secondary to other diseases. It leads to an increased blood viscosity that is associated with many complications, including ischemic events in particular. This activity illustrates the evaluation and management of secondary polycythemia and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of secondary polycythemia.</p></list-item><list-item><p>Describe the appropriate evaluation of secondary polycythemia.</p></list-item><list-item><p>Outline management options available for secondary polycythemia.</p></list-item><list-item><p>Summarize the importance of collaboration and communication amongst the interprofessional team to enhance care coordination for patients with secondary polycythemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27405&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27405">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27405.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Polycythemia, derived from poly (many) and cythemia (cells in the blood), is a condition defined as an abnormal increase in the red blood cell (RBC) mass. For a normal healthy adult, the RBC mass is 23&#x000a0;to 29 mL/kg in females and 26&#x000a0;to 32 mL/kg in males.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r2">[2]</xref> Patients with hematocrit values greater than 51% and 48% and hemoglobin values greater than 185g/L and 165 g/L in males and females, respectively, usually have an elevated RBC mass.<xref ref-type="bibr" rid="article-27405.r3">[3]</xref><xref ref-type="bibr" rid="article-27405.r4">[4]</xref> Polycythemia is not synonymous with erythrocytosis.<xref ref-type="bibr" rid="article-27405.r5">[5]</xref> Absolute erythrocytosis is defined as an&#x000a0;RBC mass greater than 125% of the predicted value adjusted for gender and body weight.<xref ref-type="bibr" rid="article-27405.r4">[4]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>Absolute or true erythrocytosis differentiates from relative polycythemia, where the hematocrit is increased, but the red cell mass lies within the normal range. The elevated hematocrit can be&#x000a0;due to the contracted plasma volume.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>An elevated erythropoietin (EPO) level, usually as a secondary response to chronic hypoxemia, leads to secondary polycythemia. Chronic hypoxemia can be secondary to various conditions, including lung pathologies like chronic obstructive pulmonary disease (COPD), airway pathologies like obstructive sleep apnea as well as muscular abnormalities like obesity hypoventilation syndrome.<xref ref-type="bibr" rid="article-27405.r7">[7]</xref></p>
      </sec>
      <sec id="article-27405.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Secondary polycythemia is due to an increased level of&#x000a0;EPO or other transcription factors that, in turn, lead to an increase in the production of&#x000a0;RBC mass. It should be noted that, unlike primary polycythemia, there is no intrinsic defect in the erythroid progenitor cell lineage. The increase in the levels of&#x000a0;EPO can be due to a number of factors, including genetic and acquired, which are discussed below.<xref ref-type="bibr" rid="article-27405.r5">[5]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>
<bold>Classification of Polycythemia</bold>
</p>
        <p>On the basis of the response of the erythroid progenitor cells to the circulating cytokines, polycythemia can be further classified into primary or secondary.<xref ref-type="bibr" rid="article-27405.r8">[8]</xref><xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
        <p>
<bold>Primary Polycythemia</bold>
</p>
        <p>Primary erythrocytosis is due to the increased proliferation of erythroid progenitor cells secondary to an intrinsic cellular defect. These patients have a suppressed erythropoietin level.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r4">[4]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref>&#x000a0;It is of two main types.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Polycythemia vera: This neoplastic disorder is the result of increased erythroid progenitor cells as well as increased sensitivity to erythropoietin secondary to a mutation called JAK mutation.</p>
          </list-item>
          <list-item>
            <p>Pure erythrocytosis: The subset of patients with pure erythrocytosis have an isolated elevated RBC mass in the absence of any other precipitating factor.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Secondary Polycythemia</bold>
<xref ref-type="bibr" rid="article-27405.r4">[4]</xref>
<xref ref-type="bibr" rid="article-27405.r6">[6]</xref>
<xref ref-type="bibr" rid="article-27405.r9">[9]</xref>
</p>
        <p>This is a heterogeneous group of disorders characterized by an elevated RBC mass due to either a&#x000a0;physiologically appropriate response to tissue hypoxia or physiologically inappropriate secretion of erythropoietin and/or other contributing factors.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref>&#x000a0;Secondary polycythemia can also be classified as congenital or acquired depending upon&#x000a0;when the individual developed the defect.<xref ref-type="bibr" rid="article-27405.r4">[4]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref>&#x000a0;Studies have revealed the presence of around 100 mutations that result in more than 50 variants of alpha and beta globulin genes associated with an increased oxygen affinity as well as mutations affecting the affinity of 2,3-bisphosphoglycerate (2,3-BPG).<xref ref-type="bibr" rid="article-27405.r2">[2]</xref> These mutations are dominantly inherited.<xref ref-type="bibr" rid="article-27405.r8">[8]</xref><xref ref-type="bibr" rid="article-27405.r10">[10]</xref><xref ref-type="bibr" rid="article-27405.r11">[11]</xref> Familial erythrocytosis results from a mutation in the hypoxia-inducible factor (HIF). A mutation in the HIF transcription factor leads to abnormal oxygen sensing and, as a result, increased production of erythropoietin and hence increased red cell mass.<xref ref-type="bibr" rid="article-27405.r11">[11]</xref><xref ref-type="bibr" rid="article-27405.r12">[12]</xref>&#x000a0;The use of anabolic steroids in athletes has been reportedly associated with increased erythrocytosis.<xref ref-type="bibr" rid="article-27405.r13">[13]</xref></p>
        <p>
<bold>Physiologically appropriate secondary polycythemia (tissue hypoxia)</bold>
</p>
        <p>
<bold>Acquired</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Central hypoxic process</p>
          </list-item>
          <list-item>
            <p>Chronic lung disease (COPD, Pickwickian syndrome)<xref ref-type="bibr" rid="article-27405.r7">[7]</xref><xref ref-type="bibr" rid="article-27405.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Right-to-left cardiopulmonary vascular shunts, cyanotic heart disease<xref ref-type="bibr" rid="article-27405.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Carbon monoxide poisoning</p>
          </list-item>
          <list-item>
            <p>Smoker&#x02019;s erythrocytosis</p>
          </list-item>
          <list-item>
            <p>Hypoventilation syndromes including obstructive sleep apnea, obesity hypoventilation syndrome<xref ref-type="bibr" rid="article-27405.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>High-altitude habitat</p>
          </list-item>
          <list-item>
            <p>Renal disease (local renal hypoxia, renal artery stenosis)</p>
          </list-item>
        </list>
        <p>
<bold>Congenital</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Hemoglobinopathy with high-oxygen-affinity</p>
          </list-item>
          <list-item>
            <p>Decreased levels of erythrocyte 2,3,-DPG</p>
          </list-item>
          <list-item>
            <p>Bisphosphoglycerate mutase deficiency</p>
          </list-item>
          <list-item>
            <p>Methemoglobinemia</p>
          </list-item>
          <list-item>
            <p>Hereditary ATP increase</p>
          </list-item>
          <list-item>
            <p>Oxygen sensing pathway gene mutations (EpoR,3 VHL,8-10 and PHD216)<xref ref-type="bibr" rid="article-27405.r5">[5]</xref><xref ref-type="bibr" rid="article-27405.r11">[11]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Physiologically Inappropriate Secondary Polycythemia</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Tumors with excessive production of erythropoietin or erythropoietin related factors (renal cell carcinoma, hepatocellular carcinoma, pheochromocytoma, cerebellar hemangioblastoma, uterine leiomyoma, ovarian carcinoma, meningioma, parathyroid carcinoma/adenomas)</p>
          </list-item>
          <list-item>
            <p>Drug associated: erythropoietin administration, androgen administration<xref ref-type="bibr" rid="article-27405.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Renal diseases including cysts, polycystic kidney disease, hydronephrosis, nephrotic syndrome, diffuse parenchymal disease, Bartter&#x02019;s syndrome, end-stage renal disease, long-term hemodialysis, post-renal transplant erythrocytosis)</p>
          </list-item>
          <list-item>
            <p>Adrenal cortical hypersecretion<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Idiopathic polycythemia<xref ref-type="bibr" rid="article-27405.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Relative Polycythemia (Gaisbock Syndrome, Spurious, or Stress Erythrocytosis)</bold>
</p>
        <p>Relative polycythemia is an elevated hematocrit marked with a normal to high normal RBC mass and low normal to decreased plasma volume.<xref ref-type="bibr" rid="article-27405.r15">[15]</xref>&#x000a0;In spite of the absence of true erythrocytosis, patients with relative polycythemia are at a higher risk for thromboembolic complications.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Chuvash Polycythemia (CP)</bold>
</p>
        <p>This endemic and recessively inherited congenital polycythemia is named after the Chuvash people in central Russia. EPO levels have been found to be significantly higher than normal. In addition to the higher EPO levels, the erythroid progenitor cells in patients with CP are hypersensitive to EPO. It is associated with a significantly increased mortality in the early years secondary to thrombotic and hemorrhagic events.<xref ref-type="bibr" rid="article-27405.r2">[2]</xref>&#x000a0;Chuvash polycythemia is associated with both primary and secondary erythrocytosis due to the underlying pathophysiology involved.<xref ref-type="bibr" rid="article-27405.r8">[8]</xref></p>
      </sec>
      <sec id="article-27405.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In a study performed by Galeus et al. (2015), COPD, congenital heart disease, and severe pulmonary hypertension were found to be among the most common etiologies&#x000a0;of secondary polycythemia. Data&#x000a0;are lacking regarding the epidemiology of secondary polycythemia.</p>
      </sec>
      <sec id="article-27405.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Erythropoiesis is the physiological process that leads to the production and maintenance of RBC mass. This process is regulated by a variety of hormones, receptors, and factors.<xref ref-type="bibr" rid="article-27405.r16">[16]</xref> EPO is the most important of all the RBC mass regulators. It is produced by the kidneys and the erythroid progenitor cells as well. Normally, EPO is produced as a response to hypoxemia and anemia. Hypoxia stimulates the production of hypoxia-inducible factors, which in turn leads to increased gene expression of EPO.<xref ref-type="bibr" rid="article-27405.r2">[2]</xref><xref ref-type="bibr" rid="article-27405.r8">[8]</xref>&#x000a0;</p>
        <p>Red blood cells are essential for oxygen transport. An increase in RBC mass will lead to increased oxygen-carrying capacity of the blood. Patients with secondary polycythemia due to a physiologically appropriate response require higher RBC mass than normal for a proper tissue oxygen delivery.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
        <p>It has been reported that a hematocrit higher than 45% is associated with hyperviscosity in normovolemic subjects. A hematocrit higher than 45% has also been associated with decreased cerebral blood flow, which is corrected after phlebotomy. There is a fine balance between the hyperviscosity and normal tissue oxygenation in such patients; that is the therapeutic goal.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
      </sec>
      <sec id="article-27405.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A detailed history and thorough physical examination usually provide clues pointing towards secondary polycythemia. A detailed history, including questions for each of the various etiological factors for secondary polycythemia, can aid in the diagnosis.</p>
        <p>Patients usually have nonspecific symptoms on the presentation that include fatigue, headache, and dizziness. In some cases, due to the hyperviscosity of blood, transient ischemic attacks lead to a transient visual defect.<xref ref-type="bibr" rid="article-27405.r14">[14]</xref> History should be focused on identifying the underlying cause. The patient should be asked about the smoking status, any history of weight loss, cough, palpitations, dyspnea, snoring, as well as the family history that is pivotal in the diagnosis of congenital causes. The patient should be asked about the usage of any anabolic steroids for muscle mass, as well as any prescription medication being used or recently used.</p>
        <p>On physical examination, scratch marks may be visible in these patients due to pruritus. Cyanosis and clubbing may also be seen. In patients who smoke, nicotinic staining of the nails and teeth can point to the underlying etiology. The body mass index of the patient, as well as the alertness, can help in identifying obstructive sleep apnea. A physical examination may reveal splenomegaly. Splenomegaly may, in turn, lead to early satiety as well. Hepatomegaly may be present in some patients. In cases with renal artery stenosis, a bruit may be heard on auscultation.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r14">[14]</xref></p>
      </sec>
      <sec id="article-27405.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The investigation of secondary polycythemia&#x000a0;includes&#x000a0;a complete blood count, which shows a raised hemoglobin and hematocrit. After an initial raised lab value, it is necessary to repeat labs once after a reasonable time interval in order to rule out a single elevated lab value.&#x000a0;Further testing with&#x000a0;renal function tests, liver function tests, ferritin levels, abdominal ultrasound, and a chest x-ray should also be performed.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref>&#x000a0;</p>
        <p>In order to establish the diagnosis of polycythemia, chromium 51-red cell mass can be evaluated along with plasma volume. However, the test is not widely available and is rarely performed inroutine clinical practice.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref> One of the frequently encountered problems is seen due to the fact that the supply of radioisotope is not available worldwide, and as a result, the&#x000a0;RBC mass calculation is difficult to perform in many centers.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>Early in the investigative workup, an erythropoietin assay must be obtained to assess the levels of EPO as it guides the further workup strategy. It differentiates between primary and secondary polycythemia.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref> An elevated EPO level points to a diagnosis of secondary polycythemia, but a normal level does not rule out secondary polycythemia as the elevations in EPO can be intermittent. In-vitro culture of the erythroid cells can also be done to diagnose secondary polycythemia. In patients with polycythemia vera, the colony formation of the progenitor cells is not dependent on the levels of erythropoietin, whereas, in cases of secondary polycythemia, the colony formation requires the presence of erythropoietin in the culture system.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
        <p>In addition to these, a JAK2 mutation must be investigated for polycythemia vera.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref> When a raised red cell mass is detected, it is necessary to rule out the presence of polycythemia vera. In order to rule out polycythemia vera (PV), iron levels and cytogenetic analysis are required. A&#x000a0;bone marrow examination may also help in ruling out PV.</p>
        <p>Pulse oximetry is essential. Oxygen saturation less than 92% suggests hypoxia, which is one of the common causes of secondary polycythemia. Measurement of arterial oxygen saturation is necessary for patients with carboxyhemoglobinemia. This is usually present in patients that smoke. In these patients, although the arterial oxygen tension is normal, oxygen saturation levels are decreased.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref> Pulmonary function tests should be done to assess the cause of hypoxemia. A sleep study can help in identifying obstructive sleep apnea as the precipitating factor.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>In patients with hemoglobinopathies that have high oxygen affinity, the oxygen dissociation curve can aid in the diagnosis. A better test in these patients is a PaO2-50, which is less than 20 in these patients.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref>&#x000a0;PaO2-50 is the partial pressure of oxygen, where 50% of hemoglobin is saturated. This can be easily calculated from venous blood samples as well and serves as the best screening test to detect high oxygen affinity.<xref ref-type="bibr" rid="article-27405.r8">[8]</xref>&#x000a0;The oxygen dissociation curve and globin gene sequencing help in evaluating the etiological factors with hemoglobin abnormalities.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>Renal diseases are also closely associated with secondary polycythemia. In order to evaluate the presence of any renal etiology, an intravenous pyelography, renal ultrasound, renal function tests, and computed tomography (CT) scan are required. In addition to that, liver ultrasonography,&#x000a0;CT scan abdomen, and radionuclide scan are also warranted with possible hepatic etiology. A CT scan of the brain with special attention to the posterior fossa can detect a cerebellar hemangioblastoma.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref>&#x000a0;</p>
        <p>Gene mutations testing for EPOR, VHL, PHD2, and HIF2A can help to diagnose a congenital etiological factor.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>A frequently encountered difficulty is the avascular nature of adipose tissue that is abundant in obese individuals, making the interpretation of these results cumbersome. Studies have shown that RBC mass expressed on the basis of body weight is lower in obese individuals. As a result, the&#x000a0;RBC mass is expressed in relation to body surface area or utilizing a formula that standardizes the red cell mass with the height and weight of the patient.</p>
        <p>If investigations reveal that red cell mass is normal, whereas the plasma volume is decreased, the raised value of hematocrit can be attributed to relative polycythemia.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
      </sec>
      <sec id="article-27405.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment approach in secondary polycythemia&#x000a0;depends on&#x000a0;the etiology involved. The general approach is the correction of the precipitating factors that will, in turn, lead to the correction of the hematologic abnormality.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
        <p>Patients who smoke should be advised to quit and be offered the appropriate supportive, psychological, and pharmacological intervention.</p>
        <p>The prescription of diuretics should be reviewed as they are associated with a contraction in the plasma volume. These should be discontinued and replaced with an appropriate alternative or dose adjusted if possible. The use of androgens is discouraged, and they should be either discontinued or the dosage should be decreased. These patients have a higher than normal requirement for iron in order to produce red cells that are normocytic and normochromic and can carry out oxygen delivery as required. Iron should be replaced in order to avoid any iron-deficient state that leads to the production of microcytic hypochromic red blood cells that are associated with a hyperviscosity state.</p>
        <p>Low flow oxygen therapy can correct hypoxia and hence the secondary polycythemia, especially in patients with chronic obstructive pulmonary disease. The use of oxygen should be judicious and closely monitored in accordance with the pulse oximetry in order to avoid any oxygen toxicity and respiratory depression in COPD patients.</p>
        <p>For patients with obesity hypoventilation syndrome, weight loss is a corrective measure that can be achieved through lifestyle modifications, pharmacological therapy, and bariatric surgery.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
        <p>Surgical removal of erythropoietin producing tumors is therapeutic in patients with this etiology. Treating benign renal lesions is also curative. In some patients with secondary polycythemia, phlebotomy can be performed for temporary relief as well.</p>
        <p>The management approach of secondary polycythemia also varies with the development of complications. Low-dose aspirin may be useful in preventing thromboembolic episodes.<xref ref-type="bibr" rid="article-27405.r17">[17]</xref>&#x000a0;This is derived from the extrapolation of studies performed for polycythemia vera. On a similar note, venesection has been found to be associated with a decreased risk of cardiovascular death and thrombosis in polycythemia vera.<xref ref-type="bibr" rid="article-27405.r18">[18]</xref> Extrapolation of these results for secondary polycythemia is usually done, keeping in view the clinical judgment of the treating clinician.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <p>In contrast to patients with secondary polycythemia due to physiologically appropriate erythrocytosis who benefit from the elevated red cell mass, patients with physiologically inappropriate erythrocytosis do not. In these patients, phlebotomy is therapeutic with goals to maintain hematocrit values of 42% to 46%. Phlebotomy should be performed in any patient with secondary polycythemia prior to any elective surgery. In patients with physiologically appropriate erythrocytosis, as the increased red cell mass is a compensatory mechanism of the body, phlebotomy should not be performed in order to maintain proper tissue oxygenation. In these patients, the therapeutic goal is the fine balance between adequate tissue oxygenation and hyperviscosity.</p>
        <p>The underlying diseases and individual responses are the determining factors for the therapeutic goal for the hematocrit. For a general idea, the goal should be to maintain hematocrit values of less than 60%.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with COPD, phlebotomy has shown a reduction in pulmonary arterial resistance and arteriovenous oxygen content difference, as well as an improved right ventricular function and hemodynamic response to exertion. These improvements are notable with hematocrits between 50%&#x000a0;to 55 %.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref><xref ref-type="bibr" rid="article-27405.r19">[19]</xref>&#x000a0;In patients with hypoxic pulmonary disease who do not respond to venesection, there are limited evidence to&#x000a0;recommend drugs like an angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>The goal hematocrit should be carefully tailored to the patients underlying etiology and on a case-to-case basis. Isovolumic phlebotomy has the advantage of preventing acute hemodynamic effects due to a reduction in blood volume.<xref ref-type="bibr" rid="article-27405.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with cyanotic heart disease, isovolumetric venesections have been recommended to be helpful in reducing viscosity. However, it should be kept in mind that excessive venesections are associated with iron deficiency.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref><xref ref-type="bibr" rid="article-27405.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>In patients diagnosed with idiopathic erythrocytosis, if the hematocrit is above 54%, then reduced to a target of 50% may be considered. For patients with comorbid conditions predisposing to a thrombotic risk and ischemia, a lower target of 45% may also be considered if already greater than 54%. In this specific group of patients, cytoreductive therapy is contraindicated.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref><xref ref-type="bibr" rid="article-27405.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Avoiding a secondary factor that predisposes to dehydration and usage of ACE inhibitors is recommended in patients with erythrocytosis secondary to post-renal transplant. The target hematocrit for this subset of patients is less than 45%.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref><xref ref-type="bibr" rid="article-27405.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Guidelines for the Management of Secondary Polycythemia</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Determination of the underlying etiology, if possible</p>
          </list-item>
          <list-item>
            <p>Recognizing and eliminating all aggravating factors</p>
          </list-item>
          <list-item>
            <p>Avoiding severe iron deficiency</p>
          </list-item>
          <list-item>
            <p>Applying specific measures in accordance with the etiology and therapeutic goal</p>
          </list-item>
          <list-item>
            <p>Considering phlebotomy for hematocrit maintenance</p>
          </list-item>
          <list-item>
            <p>Avoiding any myelosuppressive therapy</p>
          </list-item>
        </list>
        <p>
<bold>Factors to Consider Before Phlebotomy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Physiologically appropriate or inappropriate</p>
          </list-item>
          <list-item>
            <p>Adverse effects of increased red cell mass&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Presence of symptoms including dizziness, dyspnea, angina</p>
          </list-item>
          <list-item>
            <p>Previous thrombotic episodes<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27405.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for secondary polycythemia includes but is not limited to:<xref ref-type="bibr" rid="article-27405.r1">[1]</xref><xref ref-type="bibr" rid="article-27405.r4">[4]</xref><xref ref-type="bibr" rid="article-27405.r6">[6]</xref><xref ref-type="bibr" rid="article-27405.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Dehydration (causes relative polycythemia)</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease<xref ref-type="bibr" rid="article-27405.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Polycythemia vera</p>
          </list-item>
          <list-item>
            <p>Chronic smoking</p>
          </list-item>
          <list-item>
            <p>Atrial septal defect</p>
          </list-item>
          <list-item>
            <p>Ventricular septal defect (children)<xref ref-type="bibr" rid="article-27405.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Cor pulmonale</p>
          </list-item>
          <list-item>
            <p>Obstructive sleep apnea<xref ref-type="bibr" rid="article-27405.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Drug abuse<xref ref-type="bibr" rid="article-27405.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Post-renal transplant</p>
          </list-item>
          <list-item>
            <p>Renal vascular pathology, including arteriovenous malformation and renal artery stenosis</p>
          </list-item>
          <list-item>
            <p>Adrenal tumors, including incidentaloma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cancer including craniopharyngiomas, renal cancer, liver cancer, adrenal carcinoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27405.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In a study assessing mortality outcomes in a multicity cohort performed by Galeas et al., the median time from diagnosis to mortality was 21.1 months which was about 50% of that for patients with polycythemia vera. Along with this, the study also reported a 5% incidence of thrombotic episodes in patients with secondary erythrocytosis. However, the prognosis has been closely associated with the underlying etiology and the development of complications.</p>
      </sec>
      <sec id="article-27405.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Strokes due to increased erythrocytosis (also reported in the anabolic steroid use in athletes)<xref ref-type="bibr" rid="article-27405.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Venous thromboembolism&#x000a0;(low dose aspirin used for the prevention)<xref ref-type="bibr" rid="article-27405.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Pulmonary hypertension leading to hemoptysis and cardiomegaly<xref ref-type="bibr" rid="article-27405.r6">[6]</xref><xref ref-type="bibr" rid="article-27405.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Iron deficiency</p>
          </list-item>
          <list-item>
            <p>Increased whole blood viscosity</p>
          </list-item>
          <list-item>
            <p>Impaired blood supply and oxygenation</p>
          </list-item>
          <list-item>
            <p>Decreased mentation</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Generalized weakness</p>
          </list-item>
          <list-item>
            <p>Poor exercise tolerance</p>
          </list-item>
          <list-item>
            <p>Hyperviscosity</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27405.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>The following consultations may be considered in a patient undergoing workup for secondary polycythemia and for its management:<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Hematologist</p>
          </list-item>
          <list-item>
            <p>Pathologist</p>
          </list-item>
          <list-item>
            <p>Pulmonologist</p>
          </list-item>
          <list-item>
            <p>Geneticist</p>
          </list-item>
          <list-item>
            <p>Nephrologist</p>
          </list-item>
          <list-item>
            <p>Pediatrician</p>
          </list-item>
          <list-item>
            <p>Cardiologist</p>
          </list-item>
          <list-item>
            <p>Neurosurgeon</p>
          </list-item>
          <list-item>
            <p>General surgeon</p>
          </list-item>
          <list-item>
            <p>Anesthesiologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27405.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be advised to avoid dehydration and the use of any medication before proper consultation with the primary clinician. Patients should quit smoking as well as discontinue the use of alcohol. They should be educated about the symptoms of thrombosis and advised to watch for them. Limited data suggest that the use of aspirin in low doses can prevent the risk of thrombosis.</p>
        <p>Proper follow-up with the primary clinician and the specialists&#x000a0;should be encouraged. Patients should be educated about the use of anabolic steroids and their avoidance. For patients living at high altitudes, relocation can be discussed. Long-term oxygen therapy has been found helpful for patients with pulmonary diseases.<xref ref-type="bibr" rid="article-27405.r6">[6]</xref></p>
      </sec>
      <sec id="article-27405.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Elevation in the markers of coagulation activation is substantially more in polycythemia vera as compared to secondary polycythemia.<xref ref-type="bibr" rid="article-27405.r23">[23]</xref>&#x000a0;As a result, secondary polycythemia has not shown any clinical evidence of posing the patient to a higher risk of thrombosis.<xref ref-type="bibr" rid="article-27405.r7">[7]</xref>&#x000a0;Patients who have an elevated hematocrit but less than 60% may reflect an elevated RBC mass or, more commonly, a contracted plasma volume.<xref ref-type="bibr" rid="article-27405.r1">[1]</xref>&#x000a0;</p>
        <p>As&#x000a0;secondary polycythemia&#x000a0;is a rare disease, it may be a clinically challenging condition. Because this disease can be difficult to manage, patients should be referred to a specialized center in order to be managed by an interprofessional team. Secondary polycythemia lacks specific management recommendations as opposed to polycythemia vera. Many of the recommendations have been extrapolated from those of polycythemia vera due to a lack of high-level evidence.</p>
      </sec>
      <sec id="article-27405.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27405&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27405">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/secondary-polycythemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27405">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27405/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27405">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27405.s16">
        <title>References</title>
        <ref id="article-27405.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hocking</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Golde</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Polycythemia: evaluation and management.</article-title>
            <source>Blood Rev</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-65</page-range>
            <pub-id pub-id-type="pmid">2650777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prchal</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Molecular biology of polycythemias.</article-title>
            <source>Intern Med</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>681</fpage>
            <page-range>681-7</page-range>
            <pub-id pub-id-type="pmid">11518102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardiman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brunning</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Porwit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hellstr&#x000f6;m-Lindberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Jul</month>
            <day>30</day>
            <volume>114</volume>
            <issue>5</issue>
            <fpage>937</fpage>
            <page-range>937-51</page-range>
            <pub-id pub-id-type="pmid">19357394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bertozzi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cosi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Santarossa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peroni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic erythrocytosis: a study of a large cohort with a long follow-up.</article-title>
            <source>Ann Hematol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-7</page-range>
            <pub-id pub-id-type="pmid">26547864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Percy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Furlow</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>McMullin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>2193</fpage>
            <page-range>2193-6</page-range>
            <pub-id pub-id-type="pmid">17579185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMullin</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Investigation and Management of Erythrocytosis.</article-title>
            <source>Curr Hematol Malig Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>342</fpage>
            <page-range>342-7</page-range>
            <pub-id pub-id-type="pmid">27423232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nadeem</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ornstein</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of venous thromboembolism in patients with secondary polycythemia.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2013</year>
            <season>Jul-Aug</season>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>363</fpage>
            <page-range>363-6</page-range>
            <pub-id pub-id-type="pmid">23007895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maran</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prchal</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Polycythemia and oxygen sensing.</article-title>
            <source>Pathol Biol (Paris)</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>280</fpage>
            <page-range>280-4</page-range>
            <pub-id pub-id-type="pmid">15217714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patnaik</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The complete evaluation of erythrocytosis: congenital and acquired.</article-title>
            <source>Leukemia</source>
            <year>2009</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>834</fpage>
            <page-range>834-44</page-range>
            <pub-id pub-id-type="pmid">19295544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mallon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Al-Marrawi</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Holder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Talamo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drabick</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review.</article-title>
            <source>Clin Genitourin Cancer</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e391</fpage>
            <page-range>e391-5</page-range>
            <pub-id pub-id-type="pmid">26303589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Percy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Furlow</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>McMullin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Jan</month>
            <day>10</day>
            <volume>358</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-8</page-range>
            <pub-id pub-id-type="pmid">18184961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gale</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Harten</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Tuddenham</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>112</volume>
            <issue>3</issue>
            <fpage>919</fpage>
            <page-range>919-21</page-range>
            <pub-id pub-id-type="pmid">18650473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bassi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pepito</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Akhondi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Gerstmann syndrome complicating polycythemia secondary to anabolic steroid use.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Jun</month>
            <day>06</day>
            <volume>12</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31175112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pillai</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Fazal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukkamalla</surname>
                <given-names>SKR</given-names>
              </name>
              <name>
                <surname>Babiker</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <chapter-title>Polycythemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30252337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinreb</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Spurious polycythemia.</article-title>
            <source>Semin Hematol</source>
            <year>1975</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>397</fpage>
            <page-range>397-407</page-range>
            <pub-id pub-id-type="pmid">1198127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krantz</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin.</article-title>
            <source>Blood</source>
            <year>1991</year>
            <month>Feb</month>
            <day>01</day>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>419</fpage>
            <page-range>419-34</page-range>
            <pub-id pub-id-type="pmid">1991159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landolfi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marchioli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kutti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gisslinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tognoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patrono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
              <collab>European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of low-dose aspirin in polycythemia vera.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Jan</month>
            <day>08</day>
            <volume>350</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-24</page-range>
            <pub-id pub-id-type="pmid">14711910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchioli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Finazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Specchia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cacciola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cavazzina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cilloni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iurlo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Latagliata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lunghi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lunghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marfisi</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Musto</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Masciulli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Musolino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cascavilla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Randi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rumi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scortechini</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scarano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siragusa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spadea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tieghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Angelucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Visani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
              <collab>CYTO-PV Collaborative Group</collab>
            </person-group>
            <article-title>Cardiovascular events and intensity of treatment in polycythemia vera.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Jan</month>
            <day>03</day>
            <volume>368</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-33</page-range>
            <pub-id pub-id-type="pmid">23216616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weisse</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Moschos</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Levinson</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Cannilla</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels.</article-title>
            <source>Am J Med</source>
            <year>1975</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-8</page-range>
            <pub-id pub-id-type="pmid">1115064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMullin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bareford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oscier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Polkey</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>B</given-names>
              </name>
              <collab>General Haematology Task Force of the British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.</article-title>
            <source>Br J Haematol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>130</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-95</page-range>
            <pub-id pub-id-type="pmid">16029446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perloff</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Marelli</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Risk of stroke in adults with cyanotic congenital heart disease.</article-title>
            <source>Circulation</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>87</volume>
            <issue>6</issue>
            <fpage>1954</fpage>
            <page-range>1954-9</page-range>
            <pub-id pub-id-type="pmid">8504509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barenbrock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spieker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rahn</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Zidek</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis.</article-title>
            <source>Clin Nephrol</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-3</page-range>
            <pub-id pub-id-type="pmid">8261683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27405.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kornberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahimi-Levene</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yona</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rachmilewitz</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation.</article-title>
            <source>Am J Hematol</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-11</page-range>
            <pub-id pub-id-type="pmid">9298860</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
